On Jul. 8, 2020, the European Commissioy announced regulatory approval for the first adjuvanted quadrivalent influenza vaccine to become available across Europe.

The new quadrivalent vaccine is specifically designed to protect adults aged 65 and over against four strains of seasonal influenza: two A strains along with two B strains, as opposed to a two A strains and a single B strain in the current vaccine.